ZielBio

ZielBio is a clinical-stage biotechnology company dedicated to identifying novel disease targets and developing therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform, ZielFind, combines functional, high-throughput screening capabilities with large-content data analysis to identify high-value targets. ZielBio has a range of promising targets and therapies, including its lead asset ZB131, a proprietary humanized monoclonal antibody targeting cancer-specific plectin, a target identified through ZielFind.